A new company will be formed as Sumitomo aligns three of its subsidiaries-- Valent BioSciences LLC, MGK, and Valent North America—under the name Sumitomo Biorational Company.
Sumitomo Biorational Company LLC (SBC) is expected to formally launch in April 2026, be headquartered in Libertyville, Illinois, and by led by Dr. Shinsuke (Shin) Shojima, who has been appointed President and CEO.
The company says its strategy is for SBC to be Sumitomo’s global center of excellence for biorational innovation. It’s expected to accelerate the company’s capabilities in providing integrated, sustainable biorational solutions (from sources such as microbials and botanicals) to its customers.
Company leaders provided these statements in the company’s news release:
- “Valent BioSciences has a long and successful history of pioneering biorational technologies. With SBC, we build on that foundation by creating a Global Center of Excellence that accelerates the next wave of sustainable innovation for customers worldwide.” Salman Mir, President and CEO of Valent BioSciences
- “MGK has successfully developed and commercialized botanical technologies for more than 120 years. SBC strengthens our ability to bring innovative botanical solutions to market more quickly, meeting the critical needs of our customers and communities.” Steve Gullickson, President and CEO of MGK
- “Valent North America is committed to providing consistent, effective services that enable our businesses to focus on what matters most – delivering innovative sustainable solutions to meet our customer’s needs. By combining our collective strengths through SBC, we are creating a Global Center of Excellence that delivers integrated solutions to drive productivity and sustainability for our customers.” Andy Lee, President and CEO of Valent North America.
Notable, Valent U.S.A. LLC will continue to operate separately and maintain its focus on regional sales and marketing.
